Weight Loss Investigational 🔥 Trending

Pemvidutide

A balanced GLP-1 and glucagon dual agonist from Altimmune with obesity and liver-disease relevance.

GLP-1GlucagonMASHInvestigationalAltimmune

Also referenced as: ALT-801

Also appears in: Hormone

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
1

ALT-801

Signal depth
Medium

No FDA label signal · 15 trials · 15 PubMed results

Promising
Research evidence

Pemvidutide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Pemvidutide has 15 name-matched clinical trials (highest phase: Phase 2) and 15 PubMed-indexed publications and is not FDA-approved. 4 trials have posted results.

Human data
Phase 2
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Multiple trials
Literature
Top-tier journals
PHASE2 · Randomized Efficacy and Safety of ALT-801 in the Treatment of Obesity PHASE2 · Randomized IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) PHASE2 · Randomized RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight Journal of Hepatology · 144 citations Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study Clinical Cancer Research · 52 citations Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies Scientific Reports · 48 citations Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What pemvidutide is

Pemvidutide is an investigational GLP-1 / glucagon dual receptor agonist from Altimmune being developed for obesity and serious liver-disease indications.

Why it matters

Unlike some obesity candidates that are trying only to win the body-weight leaderboard, pemvidutide is increasingly important because of its MASH / liver-disease positioning and FDA Breakthrough Therapy status in that area.

Regulatory context

Pemvidutide is not FDA approved. It remains an investigational asset, but it is already one of the more visible dual-agonist names in liver-metabolic development.

Practical reading note

This is a good example of a peptide candidate whose strategic value may come as much from liver disease as from obesity itself.